Cellceutix preclinical data

In nude mice implanted subcutaneously with human retinoblastoma cells, Kevetrin significantly reduced tumor volume by >50% vs. controls. Cellceutix said Kevetrin also significantly improved clarity of the eye vs. controls, but did not disclose details. The company said that Kevetrin in retinoblastoma would qualify for a number of FDA programs, including Orphan Drug, Fast Track and Breakthrough Therapy designations. Breakthrough designation commits FDA to collaborate with a sponsor to enable expedited development and review of compounds for serious or life-threatening diseases that show substantial improvements over existing treatments in early trials. ...